scholarly journals Impact of vitamin D therapy on decreasing of proteinuria in type 2 diabetic patients

2016 ◽  
Vol 6 (1) ◽  
pp. 10-14 ◽  
Author(s):  
Ali Momeni ◽  
Mahmood Mirhosseini ◽  
Mohsen Kabiri ◽  
Soleiman Kheiri
Keyword(s):  
Vitamin D ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Type 2 Diabetic

Vitamin D3 supplementation improves glycemic control in type 2 diabetic patients: Results from an Italian clinical trial

2020 ◽  
pp. 1-10
Author(s):  
Giuseppe Derosa ◽  
Angela D’Angelo ◽  
Chiara Martinotti ◽  
Maria Chiara Valentino ◽  
Sergio Di Matteo ◽  
...  
Keyword(s):  
Vitamin D ◽  
Vitamin D Deficiency ◽  
Metabolic Control ◽  
Vitamin D3 ◽  
Therapy Group ◽  
Hypoglycemic Agents ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Type 2 Diabetic

Abstract. Background: to evaluate the effects of Vitamin D3 on glyco-metabolic control in type 2 diabetic patients with Vitamin D deficiency. Methods: one hundred and seventeen patients were randomized to placebo and 122 patients to Vitamin D3. We evaluated anthropometric parameters, glyco-metabolic control, and parathormone (PTH) value at baseline, after 3, and 6 months. Results: a significant reduction of fasting, and post-prandial glucose was recorded in Vitamin D3 group after 6 months. A significant HbA1c decrease was observed in Vitamin D3 (from 7.6% or 60 mmol/mol to 7.1% or 54 mmol) at 6 months compared to baseline, and to placebo (p < 0.05 for both). At the end of the study period, we noticed a change in the amount in doses of oral or subcutaneous hypoglycemic agents and insulin, respectively. The use of metformin, acarbose, and pioglitazone was significantly lower (p = 0.037, p = 0.048, and p = 0.042, respectively) than at the beginning of the study in the Vitamin D3 therapy group. The units of Lispro, Aspart, and Glargine insulin were lower in the Vitamin D3 group at the end of the study (p = 0.031, p = 0.037, and p = 0.035, respectively) than in the placebo group. Conclusions: in type 2 diabetic patients with Vitamin D deficiency, the restoration of value in the Vitamin D standard has led not only to an improvement in the glyco-metabolic compensation, but also to a reduced posology of some oral hypoglycemic agents and some types of insulin used.

scholarly journals Analysis of the Associations between Vitamin D and Albuminuria orβ-Cell Function in Chinese Type 2 Diabetes

2014 ◽  
Vol 2014 ◽  
pp. 1-5 ◽  
Author(s):  
Xiaoling Cai ◽  
Zhaoheng Hu ◽  
Ling Chen ◽  
Xueyao Han ◽  
Linong Ji
Keyword(s):  
Insulin Resistance ◽  
Vitamin D ◽  
Cell Function ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Albumin Creatinine Ratio ◽  
Urine Albumin ◽  
Vitamin D Supplement ◽  
Type 2 Diabetic

Objective. To investigate the associations of 25-(OH)D andβ-cell function or insulin resistance or albuminuria in Chinese type 2 diabetic patients.Methods. In total, 1408 type 2 diabetic patients without vitamin D supplement were included in this retrospective study.Results. Comparison between patients with and without 25-(OH)D deficiency indicated that, compared with patients with 25-(OH)D ≥ 50 nmol/L, patients with 25-(OH)D < 50 nmol/L showed a higher level of urine albumin-creatinine ratio (ACR) (90.15±10.30 mg/g versus52.79±14.97 mg/g). Multiple regression analysis indicated that 25-(OH)D was independently and negatively correlated with urine ACR (OR=0.985, 95%CI 0.972–0.999,P=0.03), adjusted by age, diabetic duration, HBP duration, SBP, HbA1c, creatinine, LDL-C, triglyceride, total cholesterol, and HDL-C. Compared with patients with normal level of urine ACR, patients with higher level of urine ACR showed a significant lower level of 25-(OH)D (34.49±13.52 nmol/L versus37.46±13.6 nmol/L,P=0.00). Analysis of the associations of 25-(OH)D andβ-cell function or insulin resistance showed that 25-(OH)D may not correlate withβ-cell function or insulin resistance.Conclusion. 25-(OH)D was independently associated with albuminuria in Chinese type 2 diabetic patients but was not associated withβ-cell function or insulin resistance.

scholarly journals Glycated Haemoglobin Is Inversely Related to Serum Vitamin D Levels in Type 2 Diabetic Patients

PLoS ONE ◽  
2013 ◽  
Vol 8 (12) ◽  
pp. e82733 ◽  
Author(s):  
Giacomo Zoppini ◽  
Anna Galletti ◽  
Giovanni Targher ◽  
Corinna Brangani ◽  
Isabella Pichiri ◽  
...  
Keyword(s):  
Vitamin D ◽  
Serum Vitamin ◽  
Glycated Haemoglobin ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Serum Vitamin D ◽  
Vitamin D Levels ◽  
Type 2 Diabetic

scholarly journals Effect of Vitamin D supplementation on vascular functions and oxidative stress in type 2 diabetic patients with Vitamin D deficiency

2017 ◽  
Vol 21 (4) ◽  
pp. 555 ◽  
Author(s):  
Sandhiya Selvarajan ◽  
Nishanthi Anandabaskar ◽  
StevenAibor Dkhar ◽  
SadishKumar Kamalanathan ◽  
Kadhiravan Tamilarasu ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Vitamin D ◽  
Vitamin D Deficiency ◽  
Vitamin D Supplementation ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
And Oxidative Stress ◽  
Type 2 Diabetic

scholarly journals TYPE 2 DIABETIC PATIENTS

2018 ◽  
Vol 25 (11) ◽  
pp. 1689-1695
Author(s):  
Mazhar Hussain ◽  
Muhammad Arshad Qureshi ◽  
Abdul Qudoos Arain ◽  
Habib-Ur- Rehman
Keyword(s):  
Vitamin D ◽  
Neuropathic Pain ◽  
Positive Impact ◽  
P Value ◽  
Diabetic Patients ◽  
Oral Vitamin ◽  
Type 2 Diabetic Patients ◽  
Peripheral Neuropathic Pain ◽  
Type 2 Diabetic

Background: Peripheral neuropathic pain is a devastating complication intype 2 diabetic patients with significant morbidity and mortality. Objectives: To investigate theeffect of oral vitamin D supplementation on symptoms of peripheral neuropathic pain in type 2diabetic patients. Study Design: Prospective randomized placebo controlled trial. Setting:Diabetic Clinic of Sheikh Zayed Medical College/Hospital Rahim Yar Khan. Period: Overa period of 6 months from Jan-July 2017. Methods: 116 vitamin D deficient type 2 diabeticpatients with symptoms of peripheral neuropathic pain were divided in to two groups toprescribed either oral vitamin D3 capsule 50000IU weekly or Placebo capsule for a periodof 12 weeks. Symptoms of diabetic neuropathic pain were assessed by neuropathysymptoms score (NSS) and neuropathy disability score (NDS) while Vitamin D status wasestimated by measuring the serum total 25(OH) D concentration. The primary end pointwas changes in NSS and NDS while secondary end point was changes in HbA1C and 25(OH) D concentrations from baseline. Results: After 12 weeks of vitamin D therapy, vitaminD improved its own level in interventional group (28.5±12.5 to 48.2±15.6) vs placebo group(30.6±16.2 to31.5±12.6) with p-value (0.001). This rise was accompanied by improvementin HbAIc (8.2±1.8 to 7.5±2.2) vs Placebo (7.8±1.5 to 8.0±1.8) with p-value (0.004) and NSSscore (6.02±1.5 to 4.52±0.8) vs placebo (5.82 ±1.8 to 5.65±1.5) with p-value (0.002). Howeverno significant changes were seen in NDS in both study groups. Conclusion: Oral vitamin D3therapy has positive impact on its own status as well as symptoms of peripheral neuropathicpain in type 2 diabetic patients.

Sign in / Sign up

Export Citation Format

Share Document